BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price reduced by HC Wainwright from $79.00 to $66.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2023 earnings at ($1.81) EPS, Q2 2023 […]
Hennion & Walsh Asset Management Inc. raised its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 14.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 39,185 shares of the company’s stock after acquiring an additional 4,954 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in BioXcel Therapeutics were […]
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its price objective decreased by HC Wainwright from $79.00 to $66.00 in a research note released on Tuesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2023 earnings at ($1.81) EPS, Q2 2023 […]
Equities research analysts forecast that BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) will report earnings of ($1.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for BioXcel Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.95) and the lowest estimate coming in at ($1.35). BioXcel Therapeutics […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has earned an average recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that […]